What Happened

Eli Lilly's JAK inhibitor, acquired through its purchase of Ajax Therapeutics, demonstrated positive results in a myelofibrosis study. Among 20 patients, 13 achieved a 35% reduction in spleen volume, and 17 saw a 50% or more reduction in total symptoms.

Who Is Affected

Patients with myelofibrosis who have not responded to or cannot tolerate existing JAK inhibitors like Incyte's Jakafi are the primary beneficiaries. Healthcare providers and payers in the oncology space are also impacted.

Market Impact

• Potential competition for Incyte's Jakafi, which generated $3.1 billion in 2022.
• Increased interest in JAK inhibitors designed to bind in the inactive state.
• Possible shift in treatment protocols for myelofibrosis patients.

What to Watch

Monitor larger-scale trials of Lilly's drug for continued positive results. Watch Incyte's stock performance and any strategic moves in response to this emerging competition.